{"id":3665,"date":"2018-11-22T15:55:53","date_gmt":"2018-11-22T10:25:53","guid":{"rendered":"https:\/\/www.delveinsight.com\/blog\/?p=3665"},"modified":"2021-07-24T12:57:08","modified_gmt":"2021-07-24T07:27:08","slug":"the-business-cocktail-46","status":"publish","type":"post","link":"https:\/\/www.delveinsight.com\/blog\/the-business-cocktail-46","title":{"rendered":"Cambrex acquires Avista; Sobi pays $50M; LEO Pharma signs deal; Boston Scientific remunerates"},"content":{"rendered":"<p style=\"text-align: justify;\"><strong>Cambrex takes over Avista in USD 250 Million agreement<\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>Cambrex<\/strong>, life sciences company, is taking over <strong>Avista Pharma Solutions<\/strong>\u00a0with a deal of\u00a0<strong>USD 250 million<\/strong> to become a leading <strong>contract development and manufacturing organization (CDMO)<\/strong>. The agreement includes the early-stage drug development and manufacturing capabilities of Avista to, New Jersey-based, Cambrex&#8217;s existing active pharmaceutical ingredient and finished dosage form services.<\/p>\n<p style=\"text-align: justify;\"><strong>Sobi pays USD 50 Million on a rare disease drug <\/strong><\/p>\n<p style=\"text-align: justify;\">After <strong>Sobi<\/strong> remunerated <strong>Novimmune<\/strong>\u00a0with <strong>USD 50 million<\/strong> in cash and used <strong>USD 400 million<\/strong> in milestones for a <strong>rare disease drug<\/strong> called <strong>emapalumab<\/strong>.\u00a0 The <strong>FDA<\/strong> has given a nod to it. The drug is used to treat <strong>hemophagocytic lymphohistiocytosis, or HLH<\/strong> that is an <strong>autoimmune<\/strong> condition in which cells become overactive, releasing molecules that spur inflammation. The disease affects children primarily.<\/p>\n<p style=\"text-align: justify;\"><strong>LEO Pharma signs USD 760 Million deal with PellePharm<\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>LEO Pharma<\/strong>, a pharmaceutical company, has inked a research collaboration deal with <strong>PellePharm<\/strong> for late-stage trials. This gives an option for LEO to take over the small rare disease company. The agreement commences with <strong>USD 70 million<\/strong> in <strong>equity financing<\/strong> and <strong>R&amp;D<\/strong> support to fund a global phase 3 trial for patidegib of PellePharm. PellePharm, the biotechnology company committed to target rare dermatological diseases, could receive up to <strong>USD<\/strong> <strong>690 million<\/strong> after completion of certain regulatory and commercial milestones, double-digit royalty payments as well.<\/p>\n<p style=\"text-align: justify;\"><strong>Boston Scientific remunerates USD 4.2 Billion to BTG \u00a0<\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>Boston Scientific<\/strong> gets a deal finalised of remunerating <strong>BTG,\u00a0<\/strong>healthcare company<strong>,<\/strong> for <strong>USD 4.2 billion<\/strong> in cash. This will help in acquiring a pipeline that will transform its oncology franchise into a <strong>USD 500 million<\/strong> interventional <a href=\"https:\/\/www.delveinsight.com\/report-store\/cervical-cancer-market\">cancer <\/a>therapy business. The medtech giant also assumes the deal to increase more than <strong>USD 400 million<\/strong> in revenue to its peripheral intervention segments. Also synergies between the two companies\u2019 operations amounting more than USD 175 million. BTG has 1,600 employees across\u00a0three main businesses that are cancer and vascular interventions, and a portfolio of speciality antidotes for snake bites and drug overdoses. It will give Boston Scientific the opportunity to extend into new therapies in coming years, including radiotherapies under development for lung and breast cancer.<\/p>\n<p style=\"text-align: justify;\">\n<p style=\"text-align: justify;\">\n","protected":false},"excerpt":{"rendered":"<p>Cambrex takes over Avista in USD 250 Million agreement Cambrex, life sciences company, is taking over Avista Pharma Solutions\u00a0with a deal of\u00a0USD 250 million to become a leading contract development and manufacturing organization (CDMO). The agreement includes the early-stage drug development and manufacturing capabilities of Avista to, New Jersey-based, Cambrex&#8217;s existing active pharmaceutical ingredient and [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":3668,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"_editorskit_title_hidden":false,"_editorskit_reading_time":0,"_editorskit_is_block_options_detached":false,"_editorskit_block_options_position":"{}","advgb_blocks_editor_width":"","advgb_blocks_columns_visual_guide":"","footnotes":""},"categories":[32],"tags":[1974,2212,2221,2222,2211,1404,2213,2214,2220,704,2216,2217,2218,1209,2219,702,2215,542,2223],"industry":[17225],"therapeutic_areas":[17228,17234],"class_list":["post-3665","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-notizia","tag-autoimmune","tag-avista-pharma-solutions","tag-boston-scientific","tag-btg","tag-cambrex","tag-cdmo","tag-contract-development-and-manufacturing-organization","tag-emapalumab","tag-equity-financing","tag-fda","tag-hemophagocytic-lymphohistiocytosis","tag-hlh","tag-leo-pharma","tag-novimmune","tag-pellepharm","tag-rd","tag-rare-disease-drug","tag-sobi","tag-usd-4-2-billion","industry-pharmaceutical","therapeutic_areas-oncology","therapeutic_areas-rare-diseases"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v25.8 (Yoast SEO v25.8) - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>Cambrex acquires Avista; Sobi pays $50M; LEO Pharma signs deal<\/title>\n<meta name=\"description\" content=\"Cambrex, life sciences company, is taking over Avista Pharma Solutions\u00a0with a deal of\u00a0USD 250 million to become a leading....\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.delveinsight.com\/blog\/the-business-cocktail-46\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Cambrex acquires Avista; Sobi pays $50M; LEO Pharma signs deal\" \/>\n<meta property=\"og:description\" content=\"Cambrex, life sciences company, is taking over Avista Pharma Solutions\u00a0with a deal of\u00a0USD 250 million to become a leading....\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.delveinsight.com\/blog\/the-business-cocktail-46\" \/>\n<meta property=\"og:site_name\" content=\"DelveInsight Business Research\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/DelveInsight-1423323754607782\/\" \/>\n<meta property=\"article:published_time\" content=\"2018-11-22T10:25:53+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2021-07-24T07:27:08+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2018\/11\/09020521\/medicine.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"1024\" \/>\n\t<meta property=\"og:image:height\" content=\"768\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"DelveInsight\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@DelveInsight\" \/>\n<meta name=\"twitter:site\" content=\"@DelveInsight\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"DelveInsight\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Cambrex acquires Avista; Sobi pays $50M; LEO Pharma signs deal","description":"Cambrex, life sciences company, is taking over Avista Pharma Solutions\u00a0with a deal of\u00a0USD 250 million to become a leading....","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.delveinsight.com\/blog\/the-business-cocktail-46","og_locale":"en_US","og_type":"article","og_title":"Cambrex acquires Avista; Sobi pays $50M; LEO Pharma signs deal","og_description":"Cambrex, life sciences company, is taking over Avista Pharma Solutions\u00a0with a deal of\u00a0USD 250 million to become a leading....","og_url":"https:\/\/www.delveinsight.com\/blog\/the-business-cocktail-46","og_site_name":"DelveInsight Business Research","article_publisher":"https:\/\/www.facebook.com\/DelveInsight-1423323754607782\/","article_published_time":"2018-11-22T10:25:53+00:00","article_modified_time":"2021-07-24T07:27:08+00:00","og_image":[{"width":1024,"height":768,"url":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2018\/11\/09020521\/medicine.jpg","type":"image\/jpeg"}],"author":"DelveInsight","twitter_card":"summary_large_image","twitter_creator":"@DelveInsight","twitter_site":"@DelveInsight","twitter_misc":{"Written by":"DelveInsight","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/www.delveinsight.com\/blog\/the-business-cocktail-46","url":"https:\/\/www.delveinsight.com\/blog\/the-business-cocktail-46","name":"Cambrex acquires Avista; Sobi pays $50M; LEO Pharma signs deal","isPartOf":{"@id":"https:\/\/www.delveinsight.com\/blog\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.delveinsight.com\/blog\/the-business-cocktail-46#primaryimage"},"image":{"@id":"https:\/\/www.delveinsight.com\/blog\/the-business-cocktail-46#primaryimage"},"thumbnailUrl":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2018\/11\/09020521\/medicine.jpg","datePublished":"2018-11-22T10:25:53+00:00","dateModified":"2021-07-24T07:27:08+00:00","author":{"@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/5fbf6ca478835d03fdb5e17d905b520a"},"description":"Cambrex, life sciences company, is taking over Avista Pharma Solutions\u00a0with a deal of\u00a0USD 250 million to become a leading....","inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.delveinsight.com\/blog\/the-business-cocktail-46"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.delveinsight.com\/blog\/the-business-cocktail-46#primaryimage","url":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2018\/11\/09020521\/medicine.jpg","contentUrl":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2018\/11\/09020521\/medicine.jpg","width":1024,"height":768},{"@type":"WebSite","@id":"https:\/\/www.delveinsight.com\/blog\/#website","url":"https:\/\/www.delveinsight.com\/blog\/","name":"DelveInsight Business Research","description":"Blog","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.delveinsight.com\/blog\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/5fbf6ca478835d03fdb5e17d905b520a","name":"DelveInsight","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/afdd550c64e18f6ad8957080b017c6ae55f4916951d641d3cd40264176aa0e86?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/afdd550c64e18f6ad8957080b017c6ae55f4916951d641d3cd40264176aa0e86?s=96&d=mm&r=g","caption":"DelveInsight"}}]}},"author_meta":{"display_name":"DelveInsight","author_link":"https:\/\/www.delveinsight.com\/blog\/author\/gtadmin"},"featured_img":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2018\/11\/09020521\/medicine-300x225.jpg","coauthors":[],"tax_additional":{"categories":{"linked":["<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Notizia - Recent Pharma, Healthcare and Biotech Happenings<\/a>"],"unlinked":["<span class=\"advgb-post-tax-term\">Notizia - Recent Pharma, Healthcare and Biotech Happenings<\/span>"]},"tags":{"linked":["<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">autoimmune<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Avista Pharma Solutions<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Boston Scientific<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">BTG<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Cambrex<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">CDMO<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">contract development and manufacturing organization<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">emapalumab<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">equity financing<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">FDA<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">hemophagocytic lymphohistiocytosis<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">HLH<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">LEO Pharma<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Novimmune<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">PellePharm<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">R&amp;D<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">rare disease drug<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Sobi<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">USD 4.2 billion<\/a>"],"unlinked":["<span class=\"advgb-post-tax-term\">autoimmune<\/span>","<span class=\"advgb-post-tax-term\">Avista Pharma Solutions<\/span>","<span class=\"advgb-post-tax-term\">Boston Scientific<\/span>","<span class=\"advgb-post-tax-term\">BTG<\/span>","<span class=\"advgb-post-tax-term\">Cambrex<\/span>","<span class=\"advgb-post-tax-term\">CDMO<\/span>","<span class=\"advgb-post-tax-term\">contract development and manufacturing organization<\/span>","<span class=\"advgb-post-tax-term\">emapalumab<\/span>","<span class=\"advgb-post-tax-term\">equity financing<\/span>","<span class=\"advgb-post-tax-term\">FDA<\/span>","<span class=\"advgb-post-tax-term\">hemophagocytic lymphohistiocytosis<\/span>","<span class=\"advgb-post-tax-term\">HLH<\/span>","<span class=\"advgb-post-tax-term\">LEO Pharma<\/span>","<span class=\"advgb-post-tax-term\">Novimmune<\/span>","<span class=\"advgb-post-tax-term\">PellePharm<\/span>","<span class=\"advgb-post-tax-term\">R&amp;D<\/span>","<span class=\"advgb-post-tax-term\">rare disease drug<\/span>","<span class=\"advgb-post-tax-term\">Sobi<\/span>","<span class=\"advgb-post-tax-term\">USD 4.2 billion<\/span>"]}},"comment_count":"0","relative_dates":{"created":"Posted 7 years ago","modified":"Updated 5 years ago"},"absolute_dates":{"created":"Posted on Nov 22, 2018","modified":"Updated on Jul 24, 2021"},"absolute_dates_time":{"created":"Posted on Nov 22, 2018 3:55 pm","modified":"Updated on Jul 24, 2021 12:57 pm"},"featured_img_caption":"","series_order":"","_links":{"self":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/3665","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/comments?post=3665"}],"version-history":[{"count":0,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/3665\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/media\/3668"}],"wp:attachment":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/media?parent=3665"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/categories?post=3665"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/tags?post=3665"},{"taxonomy":"industry","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/industry?post=3665"},{"taxonomy":"therapeutic_areas","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/therapeutic_areas?post=3665"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}